{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:46:05Z","timestamp":1779176765248,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["#19H03700 (Y.K.), #17K09990 (Mi.T.),"],"award-info":[{"award-number":["#19H03700 (Y.K.), #17K09990 (Mi.T.),"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan College of Rheumatology Next Generation"},{"name":"Health and Labour Sciences Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to determine the clinical efficacy of apremilast for oral ulcers (OUs), extra-oral manifestations, and overall disease activity in patients with Beh\u00e7et\u2019s disease (BD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature search was performed in PubMed, Embase, Cochrane Library, and Web of Science Core Collection. Studies assessing the treatment effects of apremilast in BD were included. The odds ratios (ORs) of being symptom-free for individual manifestations and mean difference (MD) of Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF) scores were calculated with 95% confidence intervals (CIs) at 12 and 24\u2009weeks using a random-model meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 259 screened articles, eight were included. After 12\u2009weeks of apremilast treatment the OR of symptom-free was as followings: OUs, 45.76 (95% CI, 13.23\u2013158.31); genital ulcers, 4.56 (95% CI, 2.47\u20138.44); erythema nodosum, 3.59 (95% CI, 1.11\u201311.61); pseudofolliculitis, 2.81 (95% CI, 1.29\u20136.15); and arthritis, 3.55 (95% CI, 1.71\u20137.40). Furthermore, BDCAF scores at 12\u2009weeks were significantly reduced (MD=\u22121.38; \u22121.78 to \u22120.99). However, the proportion of oral-ulcer-free patients increased at 24\u2009weeks (OR\u2009=\u200914.88; 4.81 to 46.07).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The currently accumulated data indicate an improvement in mucocutaneous and articular symptoms by short-term apremilast treatment in patients with BD.<\/jats:p><\/jats:sec>","DOI":"10.1093\/mr\/roab098","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T21:19:15Z","timestamp":1636492755000},"page":"1153-1162","source":"Crossref","is-referenced-by-count":11,"title":["Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Beh\u00e7et\u2019s disease: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"given":"Yuki","family":"Iizuka","sequence":"first","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-9274","authenticated-orcid":false,"given":"Kaoru","family":"Takase-Minegishi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hirahara","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-661X","authenticated-orcid":false,"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Soejima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-4284","authenticated-orcid":false,"given":"H o","family":"Namkoong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[{"name":"Chemotherapy Center, Yokohama City University Hospital , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-7046","authenticated-orcid":false,"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital , Kawasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"2022101711274403500_R1","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","journal-title":"Lancet"},{"key":"2022101711274403500_R2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022101711274403500_R3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","article-title":"Beh\u00e7et disease: evolution of clinical manifestations","volume":"90","author":"Ideguchi","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2022101711274403500_R4","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2169\/internalmedicine.2035-18","article-title":"Clinical and genetic aspects of Beh\u00e7et\u2019s disease in Japan","volume":"58","author":"Kirino","year":"2019","journal-title":"Intern Med"},{"key":"2022101711274403500_R5","first-page":"391","article-title":"Diagnostic criteria for Behcet\u2019s disease in 1987, and guideline for treating Behcet\u2019s disease","volume":"43","author":"Mizushima","year":"1988","journal-title":"Saishin Igaku"},{"key":"2022101711274403500_R6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"2022101711274403500_R7","article-title":"One-year period prevalence of oral aphthous ulcers and oral health-related quality of life in patients with Beh\u00e7et\u2019s disease","volume":"2014","author":"Naito","year":"2014","journal-title":"Genet Res Int"},{"key":"2022101711274403500_R8","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022101711274403500_R9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/1346-8138.15207","article-title":"Guidelines for the treatment of skin and mucosal lesions in Beh\u00e7et\u2019s disease: a secondary publication","volume":"47","author":"Nakamura","year":"2020","journal-title":"J Dermatol"},{"key":"2022101711274403500_R10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14397595.2019.1696504","article-title":"Positioning of apremilast in treatment of Beh\u00e7et\u2019s disease","volume":"30","author":"Takeno","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022101711274403500_R11","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"2022101711274403500_R12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","article-title":"The Behcet\u2019s disease activity index","volume":"43","author":"Lawton","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2022101711274403500_R13","first-page":"69","article-title":"Apremilast in refractory orogenital ulcers and other manifestations of Beh\u00e7et\u2019s disease. A national multicentre study of 51 cases in clinical practice","volume":"38","author":"Atienza-Mateo","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2022101711274403500_R14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/rheumatology\/kez267","article-title":"Efficacy and safety of apremilast for Beh\u00e7et\u2019s syndrome: a real-life single-centre Italian experience","volume":"59","author":"De Luca","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022101711274403500_R15","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"2022101711274403500_R16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/14397595.2020.1830504","article-title":"Efficacy and safety of apremilast for 3 months in Beh\u00e7et\u2019s disease: a prospective observational study","volume":"31","author":"Hirahara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2022101711274403500_R17","article-title":"The efficacy and safety of apremilast for the treatment of refractory oral ulcers of Beh\u00e7et\u2019s disease at this hospital [abstract]","volume":"31","author":"Kanayama","year":"2021","journal-title":"Modern Rheumatol"},{"key":"2022101711274403500_R18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","article-title":"Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et\u2019s disease","volume":"78","author":"Lopalco","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022101711274403500_R19","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-eular.2772","article-title":"The effects and safety of apremilast and cytokine expression in Beh\u00e7et\u2019s disease patients","volume":"80","author":"Ushio","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022101711274403500_R20","article-title":"Apremilast in refractory Beh\u00e7et\u2019s syndrome: a multicenter observational study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front Immunol"},{"key":"2022101711274403500_R21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2022101711274403500_R22","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2022101711274403500_R23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2022101711274403500_R24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13555-020-00409-4","article-title":"Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature","volume":"10","author":"Balak","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2022101711274403500_R25","first-page":"931","article-title":"Development of the BD-QoL: a quality of life measure specific to Beh\u00e7et\u2019s disease","volume":"31","author":"Gilworth","year":"2004","journal-title":"J Rheumatol"},{"key":"2022101711274403500_R26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjd.18233","article-title":"Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases","volume":"182","author":"Narang","year":"2020","journal-title":"Br J Dermatol"},{"key":"2022101711274403500_R27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022101711274403500_R28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/bjd.14667","article-title":"New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation","volume":"174","author":"Coates","year":"2016","journal-title":"Br J Dermatol"},{"key":"2022101711274403500_R29","first-page":"77","article-title":"Patient-driven assessment of disease activity in Beh\u00e7et\u2019s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Beh\u00e7et\u2019s Syndrome Activity Score","volume":"31","author":"Yilmaz","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2022101711274403500_R30","first-page":"FP10","article-title":"Iran Behcet\u2019s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology","volume":"32","author":"Davatchi","year":"1991","journal-title":"Hung Rheumatol"},{"key":"2022101711274403500_R31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/acr2.11156","article-title":"Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: a pooled safety analysis of three phase III, randomized, controlled trials","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2022101711274403500_R32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ibd.21313","article-title":"Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et\u2019s disease","volume":"17","author":"Cheon","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022101711274403500_R33","first-page":"S80","article-title":"A new mucocutaneous activity index for Beh\u00e7et\u2019s disease","volume":"32","author":"Mumcu","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022101711274403500_R34","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00296-018-4117-y","article-title":"The influence of oral health and psycho-social well-being on clinical outcomes in Beh\u00e7et\u2019s disease","volume":"38","author":"Senusi","year":"2018","journal-title":"Rheumatol Int"},{"key":"2022101711274403500_R35","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0341-7","article-title":"Genital ulcer severity score and genital health quality of life in Beh\u00e7et\u2019s disease","volume":"10","author":"Senusi","year":"2015","journal-title":"Orphanet J Rare Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab098\/42759470\/roab098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/6\/1153\/46543517\/roab098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/6\/1153\/46543517\/roab098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T12:21:44Z","timestamp":1699791704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/6\/1153\/6424467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,10]]},"published-print":{"date-parts":[[2022,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab098","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2021,11,10]]}}}